Background Statins are highly effective in reducing the risk of sudden cardiac death and other acute coronary events in patients with pre-existing ischaemic heart disease or with raised blood cholesterol levels. However, relatively little is known about how statins are used in primary care. The objectives of this study were to investigate age, sex and inter-practice variations in the prescribing of statins.
Introduction
Several studies have shown that statins are highly effective in reducing the risk of sudden cardiac death and other acute coronary events in patients with pre-existing ischaemic heart disease or with raised blood cholesterol levels. 1±5 Consequently, statins are recognized as the most potent drugs currently available for the treatment of raised blood cholesterol. The relative bene®ts of treatment with statins are similar in different groups of patients but the absolute bene®t depends on the initial level of risk. 6 Hence, the greatest absolute bene®ts are seen in patients who have both raised cholesterol levels and ischaemic heart disease. Because both of these conditions are very common, there is considerable scope for the use of statins to increase. Prescribing of statins by general practitioners (GPs) in England increased more than 10-fold between 1991 and 1997, from 0.3 million prescription items in 1991 to 3.3 million items in 1997 (Table 1) . 7 Guidance on the use of statins from the Standing Medical Advisory Committee and other organizations is likely to lead to a further increase in the use of statins. 8 In their guidance, the Standing Medical Advisory Committee recommended the use of statins for secondary prevention in all patients with a past history of myocardial infarction and a total cholesterol level of 4.8 mmol/l or greater, and in patients with a history of angina and a total cholesterol level of 5.5 mmol/l or greater. 9 Previous studies have shown that there are large age, sex and geographical differences in the use of many specialist treatments for ischaemic heart disease such as coronary angiography, revascularization treatment and cardiac rehabilitation. 10 One previous study also showed, using prescribing data aggregated at general practice level, that there are large interpractice variations in the use of statins. 11 However, there remains relatively little work on differences in management of ischaemic heart disease in primary care. The objectives of this study were to examine the use of statins in general practice to determine whether there were any differences in use depending on the age, sex and general practice of the patient.
Methods
The data on the use of statins in individual patients came from 288 general practices, total list size 2. General practices participating in the General Practice Research Database follow agreed guidelines for the recording of clinical and prescribing data, and submit anonymized patient-based clinical records to the database at regular intervals. The comprehensiveness and accuracy of the data recorded in the General Practice Research Database has been documented previously. 12 All of the 288 practices included in this analysis contributed data that passed regular quality checks throughout the period 1994±1996. The combined population of the practices had a very similar age±sex composition to the population of England and Wales. 13 
Total prescribing
Using the General Practice Research Database, we calculated the percentage of patients in each age±sex stratum who had been prescribed a statin in 1996.
Prescribing for patients with ischaemic heart disease We de®ned our group of patients with active ischaemic heart disease as patients who had ever had a diagnosis of ischaemic heart disease recorded and who had been prescribed either aspirin or a drug from British National Formulary Chapter 2 (drugs used to treat cardiovascular diseases) during 1996. We did this to help ensure that only active cases of ischaemic heart disease were included in the analysis and to exclude cases where the diagnosis of ischaemic heart disease was incorrect. Using a combination of diagnostic and prescribing data is a standard method of de®ning patients with a speci®c disease in analyses of data from the General Practice Research Database. Further details of this method have been given in a previous publication.
14 Having de®ned our subgroup of patients with ischaemic heart disease, we then determined how many of these patients had been prescribed a statin in 1996.
Inter-practice variation
We calculated the percentage of patients prescribed statins in 1996 in 284 of the practices in the study for all patients and for the subgroup of patients with ischaemic heart disease (four practices with list sizes of less than 1000 patients were excluded from the inter-practice analysis). We then compared the univariate association between these rates and the recorded prevalence of ischaemic heart disease in the practices using Pearson's correlation coef®cient.
Results
In 1996, 0.7 per cent of men and 0.5 per cent of women were prescribed statins by GPs in England and Wales. The percentage of patients prescribed statins was highest in people aged 55±74 years (Table 2) , in whom 2.5 per cent of patients were prescribed statins in 1996. In people aged under 65 years of age, prescribing rates were higher in men than in women, but in older patients rates were similar in men and women. The great majority (88 per cent, 11 366/12 928) of patients prescribed statins were in the 45±74 years age group.
Patients with ischaemic heart disease
The overall age-standardized prevalence of ischaemic heart disease in 1996 was 34.7 per 1000 in men and 20.8 per 1000 in women. Among patients with ischaemic heart disease, 13.3 per cent of men and 8.2 per cent of women were prescribed statins in 1996 ( Table 2 ). Use of statins was highest in men aged 35±44 years, with 31 per cent of men in this age group receiving statins in 1996. There was then a steady decrease in the use of statins in men with age. In women with ischaemic heart disease, there were much smaller differences between age groups, with the percentage of women with ischaemic heart disease prescribed statins varying between 12 and 18 per cent in women under 75 years of age. Below the age of 65 years, men with ischaemic heart disease were more likely to receive statins than were women. In patients aged 65±74 years, the use of statins was similar in men and women. Patients aged 75 years and over with ischaemic heart disease were unlikely to be prescribed a statin, irrespective of their sex.
Inter-practice differences
Both the recorded prevalence of ischaemic heart disease and the use of statins in 1996 varied widely in the 284 practices included in the examination of inter-practice differences in prescribing ( Table 3 ). The unadjusted prevalence of ischaemic heart disease varied from 9 to 71 per 1000 in men and from 10 276 JOURNAL OF PUBLIC HEALTH MEDICINE There was a strong association between the reported prevalence of ischaemic heart disease in men and women in the 284 practices (r 0.81, p < 0.0001). The correlation between the proportion of men and the proportion of women in each practice prescribed statins was 0.67 ( p < 0.0001). Among patients with ischaemic heart disease, the correlation between the proportion of men and the proportion of women prescribed statins was 0.53 ( p < 0.0001). There were only moderately strong univariate correlations between the prevalence of ischaemic heart disease and the overall use of statins (r 0.34, p < 0.0001 in men; r 0.27, p < 0.0001 in women).
Discussion
Our study has shown that there are large age, sex and practice variations in the use of statins in primary care. However, as the practices in the General Practice Research Database are volunteers, they may be atypical and therefore there may be an even greater variation in the use of statins among general practices in England and Wales than those reported in this paper. Unlike some previous studies, our study was able to examine prescribing using data derived from individual patient records and did not solely use routine prescribing data aggregated at practice or geographical level. 15 Hence, the ecological fallacy is less of a problem with this study than with many other studies of statin prescribing. One of these previous studies showed that there was considerable variation between general practices in the use of statins. 11 What was not clear was whether such differences re¯ected the differing needs of practice populations. We found that the large inter-practice differences in the use of statins are explained to only a very limited extent by the prevalence of ischaemic heart disease at practice level. Variations in the recorded prevalence of ischaemic heart disease at practice level explained just 12 per cent of the variation of prescribing of statins in men and 7 per cent in women.
Patients with ischaemic heart disease
Sex differences in the use of statins in patients with ischaemic heart disease were mainly con®ned to patients under 65 years of age, with men more likely than women to receive statins. For this analysis, we had no information on other risk factors such as diabetes or cholesterol levels. Hence, we were not able to determine whether differences between men and women in the use of statins re¯ected differences in the risk of suffering an acute coronary event. Patients aged 75 years and over were unlikely to receive statins irrespective of their sex. This may re¯ect the lack of evidence of the ef®cacy of statins in older patients because of their exclusion from many of the trials examining the effectiveness of statins and also the potential costs of extending the use of statins to this group.
Explanations for ®ndings
There are a number of possible explanations for these ®ndings. One explanation is that the ®ndings are due to errors in the data and to incomplete recording. However, although there will be differences in the accuracy and completeness of data recording in the practices that provided the data for this study, it seems unlikely that errors in the data alone could account for such large differences. Some of the variation may also be due to differences in the age structure of the patient populations registered with the practices in the study. However, a more likely explanation is that the introduction of statins into general practice, like that of many other new drugs, developed in an unstructured manner. 16 Some GPs are more ready to use new drugs than others, and the patients in whom statins were ®rst used may not always have been those most in need of cholesterol lowering medication. 17 The lack of clear guidance on the use of statins during the period of this study (1996) may have exacerbated this problem. There is always a lag between publication of evidence of the effectiveness of an intervention and take-up of the intervention in practice. The ®rst randomized controlled trials showing the effectiveness of statins in patients with hypercholesterolaemia and ischaemic heart disease were published in 1994 1 and it was only in 1997 that the Standing Medical Advisory Committee published its own guidelines on the use of statins. Hence, many doctors may not have been aware of the bene®ts of statins until this advice and other guidance on the use of statins were published.
There is now a plethora of guidelines for the use of cholesterol lowering medication and their differing recommendations may lead to some confusion among both GPs and hospital physicians as to which patients it is most appropriate to treat. 18±20 The use of more objective methods of assessing risk may help GPs in deciding which patients should be prescribed statins and in ensuring that these drugs are used in patients who will gain the greatest bene®t. 21 As awareness of the bene®ts of statins among GPs increases, it may be that the variation in prescribing rates between general practices decreases.
Implications for practice
In 1996, more than half of all patients with ischaemic heart disease in each age group examined in this study were not being treated with statins. This suggests that there is still considerable scope for the prescribing of statins to increase, particularly if they were used more frequently in older patients, in whom ischaemic heart disease is most common. 22 The use of statins for the primary prevention of ischaemic heart disease would increase the prescribing of statins still further. Inevitably, new drugs for other common chronic diseases in primary care will be introduced by pharmaceutical companies in the future. Because of the pressures on the NHS to control general practice prescribing costs, 23 ensuring that such drugs are introduced appropriately into clinical practice will be a major challenge for GPs, primary care groups and the National Institute of Clinical Excellence.
